Clinical trial · Interventional
Treatment of Malignant Tumors With NK Cell
Clinical Study of Decitabine Combined With NK Cell Infusion in the Treatment of Malignant Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells, which are a type of lymphocytes that can non-specifically kill tumor cells and virus-infected cells without pre-sensitization. NK cells can not only directly kill malignant diseased cells, but also participate in the regulation of immune cell response and play a role in a variety of tumor immunotherapy strategies. The 2-year survival rate of NK cells combined with stem cell therapy for patients with hematological malignancies reached 36%, which is significantly higher than the 2-year survival rate (about 15%) of stem cell therapy alone, which can extend the disease-free survival period of leukemia patients by an average of 1.5 years. Relapsed and refractory leukemia can achieve a complete remission rate of up to 40%.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignancy | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Decitabine combined with NK cell infusion | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment group
- description
- Decitabine combined with NK cell infusion as post-remission therapy
- interventionNames
- Biological: Decitabine combined with NK cell infusion
Primary outcomes (1)
- measure
- Disease-free survival
- timeFrame
- From date of initial treatment to the end of follow up, up to 2 years
- description
- DFS
Secondary outcomes (1)
- measure
- Overall survival rate
- timeFrame
- From admission to the end of follow up, up to 2 years.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female patients aged 18-70 (including 18 and 70 years old); 2. Those who have been diagnosed as malignant tumor by pathological and histological examination, have received anti-tumor treatment and are in remission; 3. The ECOG score of the patient is less than 2 points; 4. The patient did not receive any chemotherapy, radiotherapy, immunotherapy (such as immunosuppressive drugs) and other anti-tumor treatments within 4 weeks before enrollment, and his previous treatment-related toxicity had returned to grade \<1 (hair loss, peripheral nerves) at the time of enrollment Except for low-level toxicity such as inflammation); 5. The patient's intravenous access is unobstructed, which can meet the needs of intravenous drip; 6. The patient voluntarily participates and signs an informed consent form, and follows the research treatment plan and visit plan. Exclusion Criteria: 1. The patients used high-dose hormones within 1 week before enrollment (except for patients using inhaled hormones); 2. People with severe autoimmune diseases, immunodeficiency diseases or severe allergies; 3. Patients who have been treated with other cellular immune products (DC, T, CTL, CAR-T, etc.); 4. The patient had an uncontrollable infection within 4 weeks before enrollment; 5. Active B HBV DNA\>1000copy/mL/C virus hepatitis (anti-HCV positive, HCV RNA positive), HIV positive, syphilis positive; 6. The patient has participated in other clinical studies within 6 weeks before enrollment; 7. Patients suffering from mental illness; 8. The patient has drug abuse/addiction and medical, psychological or social conditions that may interfere with research or have an impact on the evaluation of research results; 9. The patient has alcohol dependence; 10. Women who are pregnant (positive urine/blood pregnancy studies) or breastfeeding; men or women who have a pregnancy plan within the past year; patients cannot be guaranteed to take effective contraceptive measures during the study period; 11. According to the judgment of the investigator, the patient has other conditions that are not suitable for enrollment.
References
Publications (0)
Data not yet available